SCHEMBL11940562

SCHEMBL11940562

N#CCc1ccc(CSC(=N)N)c2cccnc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 6/20 0.46
HPGD P15428 2/20 0.46
SLC11A2 P49281 1/20 0.45
LMNA P02545 4/20 0.43
BRD4 O60885 1/20 0.40
IDO1 P14902 9/20 0.38
SMN1; SMN2 Q16637 5/20 0.38
TAAR1 Q96RJ0 2/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 1/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TP53 P04637 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
HIF1A Q16665 1/20 0.37
NOS1 P29475 2/20 0.36
NOS3 P29474 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11940575 0.95 SLC11A2 (0.45) HTTHPGDSLC11A2LMNABRD4
SCHEMBL11940555 0.82 HTT (0.58) HTTHPGDSLC11A2LMNAIDO1
SCHEMBL13028720 0.82 KDM4E (0.38) HTTLMNABRD4SMN1; SMN2KDM4E
SCHEMBL11940581 0.81 HTT (0.42) HTTHPGDSLC11A2LMNAIDO1
SCHEMBL11940572 0.80 SLC11A2 (0.43) HTTHPGDSLC11A2LMNAIDO1
SCHEMBL11940573 0.79 LMNA (0.47) HTTHPGDSLC11A2LMNAIDO1
SCHEMBL11940553 0.79 LMNA (0.47) HTTHPGDSLC11A2LMNAIDO1
SCHEMBL11940547 0.78 SLC11A2 (0.43) HTTHPGDSLC11A2LMNAIDO1
SCHEMBL11940577 0.78 LMNA (0.41) HTTHPGDSLC11A2LMNAIDO1
SCHEMBL11940567 0.77 HTT (0.40) HTTHPGDSLC11A2LMNAIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9610275-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2017-04-04 US disclosed
US-9340491-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2016-05-17 US disclosed
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2013-09-19 US disclosed
US-8338454-B2 Nitrile derivatives and their pharmaceutical use and compositions CELLCEUTIX CORPORATION (US) 2012-12-25 US disclosed
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION 2012-07-26 US disclosed
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CELLCEUTIX CORPORATION (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130245062-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 HTT 2947/4885HPGD 104/4885SLC11A2 914/4885
US-20120189537-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 HTT 2947/4885HPGD 104/4885SLC11A2 914/4885
US-20100298374-A1 NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS NOS1, NOS2, NOS3 HTT 2947/4885HPGD 104/4885SLC11A2 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.